Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam, Nastech Take Different IP Approaches To Pandemic Flu RNAi Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnylam predicts companies will come knocking on its door to license its intellectual property in the field.

You may also be interested in...



Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward

Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.

Alnylam Delays IND For RNAi Flu Therapy; Nastech RNAi Program Moves Forward

Nastech shows positive preclinical results with delivery technology for RNAi targeting influenza A.

Tacere Inks Deal With Oncolys BioPharma For RNAi Candidate

Tacere Therapeutics has entered into a strategic alliance with Tokyo-based Oncolys BioPharma to develop its lead RNA interference-based candidate for treatment of hepatitis C, the companies announced June 21

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel